Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
HOUSTON, July 19, 2017 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company’s proprietary liposomal delivery and antisense technology, DNAbilize™, including its use in the treatment of cancers, autoimmune diseases and infectious diseases.
“We are particularly encouraged by the expanding role of our proprietary liposomal delivery and antisense technology as a treatment for a variety of cancers, autoimmune diseases and infectious diseases. This patent further bolsters our intellectual property position and provides us with additional opportunities to build upon this important technology,” said Peter H. Nielsen, Chief Executive Officer of Bio-Path Holdings.
The new patent, titled “P-Ethoxy Nucleic Acids for Liposomal Formulation,” (based on Application No. 15/294,223) will provide broad protection for application of the DNAbilize™ technology in the treatment of a variety of cancers, as well as autoimmune and infectious diseases. DNAbilize™ is a proprietary liposomal delivery and antisense technology, designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information: Investors Will O’Connor Stern Investor Relations, Inc. 212-362-1200 [email protected] Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369
